Ketorolac S.A.L.F.: Uses, Dosage & Side Effects

What Is Ketorolac S.A.L.F. and What Is It Used For?

Ketorolac S.A.L.F. contains the active substance ketorolac tromethamine, a member of the pyrrolizine group of nonsteroidal anti-inflammatory drugs (NSAIDs). Ketorolac was first synthesized in the early 1980s and was approved for clinical use by the U.S. Food and Drug Administration (FDA) in 1989, initially marketed under the brand name Toradol. Ketorolac S.A.L.F. is manufactured by S.A.L.F. S.p.A. Laboratorio Farmacologico, an Italian pharmaceutical company, and is available as a sterile solution for injection containing 30 mg of ketorolac tromethamine per milliliter.

As an NSAID, ketorolac exerts its therapeutic effects primarily through the inhibition of cyclooxygenase (COX) enzymes, specifically both COX-1 and COX-2. These enzymes catalyze the conversion of arachidonic acid to prostaglandins, which are lipid mediators involved in inflammation, pain signaling, and fever. By blocking prostaglandin synthesis, ketorolac produces potent analgesic (pain-relieving), anti-inflammatory, and antipyretic (fever-reducing) effects. What distinguishes ketorolac from other NSAIDs is its remarkably strong analgesic activity. While most NSAIDs provide moderate analgesia, ketorolac demonstrates analgesic potency that is comparable to moderate-dose opioid medications. Clinical studies have consistently shown that a single 30 mg intramuscular dose of ketorolac provides pain relief equivalent to approximately 10–12 mg of morphine given intramuscularly, making it one of the most potent non-opioid analgesics available.

The mechanism of ketorolac's superior analgesic activity is related to its preferential inhibition of peripheral COX enzymes at sites of tissue injury and inflammation. By suppressing prostaglandin production at the site of surgical trauma, injury, or visceral inflammation, ketorolac effectively reduces the sensitization of peripheral nociceptors (pain receptors) and decreases the transmission of pain signals to the central nervous system. This peripheral mechanism of action distinguishes it from centrally acting analgesics such as opioids, which work primarily by activating mu-opioid receptors in the brain and spinal cord.

Ketorolac S.A.L.F. injection is indicated for the short-term management of moderate to severe acute pain that would otherwise require opioid-level analgesia. The most common clinical indications include:

• Postoperative pain: Ketorolac is widely used for pain management following surgical procedures, including orthopedic, abdominal, gynecological, and dental surgery. It is frequently incorporated into multimodal analgesia protocols, where it is combined with local anesthetics, acetaminophen (paracetamol), and reduced doses of opioids to achieve superior pain control while minimizing opioid-related side effects.
• Renal colic: Ketorolac has demonstrated excellent efficacy in the management of acute renal colic (kidney stone pain). Randomized controlled trials have shown that ketorolac is at least as effective as opioids for renal colic and may be superior in terms of reduced nausea, vomiting, and need for rescue medication.
• Acute musculoskeletal pain: Severe acute pain from fractures, dislocations, sprains, and other musculoskeletal injuries can be effectively managed with ketorolac injection, particularly in emergency department settings.
• Migraine and headache: Parenteral ketorolac has shown efficacy in the acute treatment of severe migraine headaches and is used in emergency departments as a non-opioid alternative for migraine that has not responded to first-line treatments.
• Biliary colic: Ketorolac can be used for the management of acute biliary colic (gallstone pain), often in combination with antispasmodic agents.

It is critically important to understand that ketorolac injection is intended only for short-term use. The parenteral formulation is limited to a maximum treatment duration of 2 days. If continued analgesic therapy is required beyond this period, patients may be transitioned to oral ketorolac for a combined maximum treatment duration of 5 days (parenteral plus oral). This strict time limitation was established following post-marketing surveillance data that demonstrated a significantly increased incidence of serious adverse effects, particularly gastrointestinal hemorrhage, with longer durations of treatment. Regulatory agencies worldwide, including the FDA, EMA, and national drug agencies, enforce this short-term usage restriction.

What Should You Know Before Taking Ketorolac S.A.L.F.?

Contraindications

Ketorolac S.A.L.F. is absolutely contraindicated in a number of clinical situations. Administering ketorolac to patients with any of these conditions can result in serious or life-threatening complications. Healthcare providers must carefully screen all patients before initiating treatment.

Ketorolac must not be used in patients with active peptic ulcer disease or a history of gastrointestinal bleeding, ulceration, or perforation. NSAIDs including ketorolac inhibit the production of protective prostaglandins in the gastrointestinal mucosa, particularly prostaglandin E2 and prostacyclin, which are essential for maintaining mucosal blood flow, stimulating mucus and bicarbonate secretion, and promoting epithelial cell regeneration. Without this protective prostaglandin barrier, the gastric and duodenal mucosa becomes vulnerable to damage from gastric acid and pepsin, which can lead to mucosal erosion, ulceration, and potentially life-threatening hemorrhage or perforation.

Patients with moderate to severe renal impairment (creatinine clearance below 30 ml/min) must not receive ketorolac. The kidneys rely on prostaglandins, particularly PGE2 and PGI2, to maintain adequate renal blood flow, especially under conditions of decreased effective circulating volume such as dehydration, heart failure, or cirrhosis. By inhibiting prostaglandin synthesis, ketorolac can precipitate acute renal failure in patients with compromised renal function. Additionally, ketorolac is primarily eliminated by the kidneys, and impaired renal function leads to drug accumulation and increased toxicity.

Ketorolac is contraindicated during the perioperative period of coronary artery bypass graft (CABG) surgery. Large-scale clinical studies and meta-analyses have demonstrated that NSAIDs, including COX-2 selective agents, are associated with an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, in the setting of CABG surgery. This contraindication applies to all NSAIDs and is a black-box warning mandated by the FDA.

Patients with known hypersensitivity to ketorolac tromethamine, aspirin, or other NSAIDs must not receive this medication. NSAID hypersensitivity can manifest as bronchospasm, urticaria, angioedema, or anaphylaxis, and cross-reactivity among different NSAIDs is well-documented. Patients with the classic triad of aspirin-exacerbated respiratory disease (nasal polyps, asthma, and aspirin sensitivity) are at particularly high risk.

Warnings and Precautions

Even in patients without absolute contraindications, ketorolac must be used with considerable caution and at the lowest effective dose for the shortest duration possible. Several important warnings and precautions apply to all patients receiving this medication.

Gastrointestinal risk: All NSAIDs carry a risk of gastrointestinal adverse effects, but ketorolac carries a particularly elevated risk due to its potency and the typical patient population (postoperative patients who may be nil by mouth or have reduced oral intake). Risk factors for NSAID-related gastrointestinal complications include advanced age (over 65 years), history of peptic ulcer disease, concomitant use of corticosteroids or anticoagulants, smoking, alcohol consumption, and longer duration of NSAID therapy. Gastrointestinal bleeding from ketorolac can occur without warning symptoms and can be fatal.

Cardiovascular risk: NSAIDs may increase the risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke. This risk may increase with longer duration of use and in patients with pre-existing cardiovascular disease or risk factors. Ketorolac should be used with extreme caution in patients with a history of ischemic heart disease, cerebrovascular disease, peripheral arterial disease, or uncontrolled hypertension.

Renal effects: Ketorolac should be used with caution in patients with any degree of renal impairment, dehydration, or hypovolemia. Adequate hydration must be ensured before and during ketorolac administration. Elderly patients are particularly susceptible to NSAID-related renal toxicity. Serum creatinine and estimated glomerular filtration rate should be monitored in at-risk patients.

Bleeding risk: Ketorolac inhibits platelet aggregation through COX-1 inhibition and may prolong bleeding time. It should be used with caution in patients with coagulation disorders or who are receiving anticoagulant therapy. Ketorolac should be avoided in patients at high risk of hemorrhage or those undergoing procedures with a high risk of bleeding.

Pregnancy and Breastfeeding

Ketorolac is contraindicated during the third trimester of pregnancy (from week 28 onwards). NSAID use in late pregnancy is associated with several serious risks to the fetus and newborn, including premature closure of the ductus arteriosus (which can lead to persistent pulmonary hypertension of the newborn), oligohydramnios due to reduced fetal urine production, and fetal renal dysfunction. Additionally, NSAIDs can inhibit uterine contractions, potentially prolonging labor and increasing the risk of maternal hemorrhage.

During the first and second trimesters of pregnancy, ketorolac should only be used if the potential benefit clearly outweighs the risk to the fetus. Animal reproduction studies with ketorolac have shown evidence of increased peri-implantation loss and decreased fetal weight at doses that produced maternal toxicity. There are no adequate and well-controlled studies in pregnant women.

Ketorolac is excreted in human breast milk in small quantities. A single study of 10 lactating women receiving ketorolac 10 mg orally four times daily found that maximum milk concentrations were approximately 7.3 nanograms per milliliter, resulting in a low relative infant dose. However, because of the potential for serious adverse reactions in nursing infants and the lack of comprehensive safety data, the use of ketorolac during breastfeeding should be approached with caution. The decision to discontinue breastfeeding or the drug should take into account the importance of the medication to the mother.

How Does Ketorolac S.A.L.F. Interact with Other Drugs?

Drug interactions are a critical consideration when prescribing ketorolac, as the medication is frequently administered in clinical settings where patients may be receiving multiple concomitant medications. The following interactions are particularly important from a clinical perspective.

Major Interactions

Anticoagulants (warfarin, heparin, direct oral anticoagulants): Ketorolac significantly increases the risk of bleeding when combined with anticoagulant medications. This interaction occurs through two mechanisms: ketorolac inhibits platelet aggregation through COX-1 inhibition, and it can displace warfarin from plasma protein binding sites, potentially increasing the free (active) concentration of warfarin. Additionally, ketorolac increases the risk of gastrointestinal ulceration and bleeding, which is compounded by the anticoagulant effect. If concomitant use is unavoidable, close monitoring of international normalized ratio (INR) and clinical signs of bleeding is mandatory.

Other NSAIDs (including low-dose aspirin): The concomitant use of ketorolac with other NSAIDs is contraindicated. Combining two or more NSAIDs does not provide additional analgesic benefit but dramatically increases the risk of serious gastrointestinal bleeding, ulceration, and perforation. Even low-dose aspirin for cardiovascular prophylaxis increases the gastrointestinal risk when combined with ketorolac. If a patient requires aspirin for cardiovascular protection, the decision to administer ketorolac must be made carefully, weighing the analgesic benefit against the increased bleeding risk.

Lithium: NSAIDs including ketorolac can increase serum lithium concentrations by reducing renal lithium clearance. This occurs because prostaglandins normally promote renal sodium and water excretion; when prostaglandin synthesis is inhibited, sodium reabsorption increases, leading to increased lithium reabsorption in the proximal tubule. Patients receiving lithium and ketorolac should have serum lithium levels monitored closely, and the lithium dose may need to be adjusted.

Methotrexate: Ketorolac can reduce the renal clearance of methotrexate, leading to elevated and potentially toxic methotrexate plasma concentrations. This interaction is particularly dangerous with high-dose methotrexate regimens used in oncology, where even small changes in clearance can lead to severe bone marrow suppression, mucositis, and hepatotoxicity. The combination should be avoided with high-dose methotrexate; with low-dose methotrexate (e.g., for rheumatoid arthritis), extreme caution and close monitoring are required.

Minor Interactions

ACE inhibitors and ARBs: Ketorolac may reduce the antihypertensive effect of ACE inhibitors (e.g., enalapril, ramipril) and angiotensin II receptor blockers (ARBs, e.g., losartan, valsartan) by inhibiting renal prostaglandin synthesis, which is important for maintaining renal blood flow in patients taking these medications. Additionally, the combination of NSAIDs with ACE inhibitors or ARBs increases the risk of acute renal failure, particularly in dehydrated patients or those with pre-existing renal impairment. The triple combination of an NSAID, ACE inhibitor/ARB, and diuretic (the so-called "triple whammy") poses an especially high risk of acute kidney injury.

Diuretics: NSAIDs can reduce the diuretic and antihypertensive effects of both loop diuretics (e.g., furosemide) and thiazide diuretics by inhibiting renal prostaglandin-mediated natriuresis. This can lead to fluid retention and worsening of hypertension or heart failure. As noted above, the combination with ACE inhibitors/ARBs and diuretics is particularly hazardous for renal function.

SSRIs: Selective serotonin reuptake inhibitors (e.g., fluoxetine, sertraline, paroxetine) impair platelet serotonin uptake, which is important for normal platelet aggregation. When combined with ketorolac, which also inhibits platelet function through COX-1 inhibition, the risk of gastrointestinal bleeding is further increased. Patients receiving both medications should be monitored for signs of bleeding.

Corticosteroids: The concomitant use of systemic corticosteroids with ketorolac increases the risk of gastrointestinal ulceration and bleeding. Corticosteroids impair wound healing and mucosal repair, while ketorolac reduces the protective prostaglandin barrier, creating a synergistic risk for gastrointestinal complications.

What Is the Correct Dosage of Ketorolac S.A.L.F.?

Adults (Under 65 Years)

For adult patients under the age of 65 with normal renal function and body weight above 50 kg, the recommended dose of Ketorolac S.A.L.F. is 30 mg administered intramuscularly (IM) or intravenously (IV) as a single dose, which may be repeated every 6 hours as needed for pain relief. The maximum daily dose by the parenteral route is 120 mg (four doses of 30 mg). For intravenous administration, the injection should be given over a minimum of 15 seconds as a slow bolus. Intramuscular injections should be given deeply into a large muscle mass, with the injection site varied between doses to minimize local tissue irritation.

The onset of analgesic action following intramuscular injection typically occurs within 30 minutes, with peak effect at approximately 1–2 hours and a duration of action of 4–6 hours. Intravenous administration provides a somewhat faster onset, with pain relief often beginning within 15–30 minutes. The choice between IM and IV routes depends on clinical circumstances and the availability of venous access. In the postoperative setting, IV ketorolac is often preferred for its more rapid onset and the convenience of administration through an existing intravenous line.

Children

The use of ketorolac in pediatric patients varies by regulatory jurisdiction. In many countries, injectable ketorolac is approved for use in children aged 2 years and older for the short-term management of moderate to severe postoperative pain. When used in pediatric patients, the recommended dose is typically 0.5 mg/kg IM or IV (up to a maximum of 15 mg per dose), which may be repeated every 6 hours as needed. The maximum daily dose in pediatric patients is 60 mg/day, and the maximum duration of parenteral treatment remains 2 days.

It is important to note that pediatric dosing recommendations may vary between different countries and formulations. In some jurisdictions, ketorolac injection is not approved for pediatric use at all. Healthcare providers should refer to their local prescribing information and institutional guidelines. Ketorolac should not be used in neonates or infants under 2 years of age due to insufficient safety and efficacy data.

Elderly Patients (65 Years and Older)

Elderly patients are at substantially increased risk for NSAID-related adverse effects, including gastrointestinal bleeding, renal impairment, and cardiovascular events. For patients aged 65 years and older, the dose of ketorolac must be reduced. The recommended dose is 15 mg IM or IV, which may be repeated every 6 hours as needed, up to a maximum daily dose of 60 mg/day. The same dose reduction applies to patients weighing less than 50 kg, regardless of age, and to patients with any degree of renal impairment (creatinine clearance 30–60 ml/min).

Missed Dose

Since ketorolac injection is administered by healthcare professionals in clinical settings (hospitals, emergency departments, surgical centers), missed doses are uncommon. If a scheduled dose is missed, it should be given as soon as it is remembered, provided that the minimum dosing interval of 6 hours between doses is maintained. The missed dose should not be doubled to compensate. If significant time has elapsed since the scheduled dose, the healthcare provider should reassess whether the patient still requires ketorolac analgesia or whether an alternative pain management strategy is more appropriate.

Overdose

Overdose with ketorolac can result in a range of symptoms depending on the amount ingested and the route of administration. Symptoms of ketorolac overdose may include nausea, vomiting, epigastric pain, gastrointestinal bleeding, drowsiness, dizziness, headache, tinnitus, metabolic acidosis, and in severe cases, acute renal failure, respiratory depression, and coma. There have been rare reports of fatal outcomes following massive NSAID overdose, typically associated with multi-organ failure.

There is no specific antidote for ketorolac overdose. Management is primarily supportive and symptomatic. Gastric decontamination with activated charcoal may be considered if oral ingestion has occurred within 1 hour (not applicable for parenteral overdose). Treatment includes monitoring of vital signs, renal function, and electrolytes; administration of intravenous fluids to maintain hydration and urine output; and management of gastrointestinal bleeding with proton pump inhibitors if indicated. Hemodialysis does not significantly remove ketorolac from the body due to its high plasma protein binding (>99%).

What Are the Side Effects of Ketorolac S.A.L.F.?

Like all NSAIDs, ketorolac can cause a range of adverse effects that vary in frequency and severity. Understanding the side effect profile is essential for both healthcare providers and patients to enable early recognition and appropriate management. The adverse effects of ketorolac are classified according to their frequency of occurrence based on pooled data from clinical trials and post-marketing surveillance.

It is important to note that the incidence of many adverse effects, particularly gastrointestinal and renal complications, is strongly correlated with both the dose of ketorolac used and the duration of treatment. This dose- and duration-dependent risk profile is the primary reason for the strict limits on treatment duration. Patients receiving ketorolac within the recommended dose and duration guidelines have a substantially lower risk of serious complications compared to those who exceed these limits.

The following classification uses standard frequency categories: Very common (affects more than 1 in 10 patients), Common (1 in 10 to 1 in 100), Uncommon (1 in 100 to 1 in 1,000), and Rare (fewer than 1 in 1,000).

Patients should be advised to seek immediate medical attention if they experience any signs of gastrointestinal bleeding (black or tarry stools, vomiting blood or material that resembles coffee grounds, unexplained severe abdominal pain), allergic reactions (difficulty breathing, swelling of the face or throat, severe skin rash), cardiovascular events (chest pain, sudden weakness on one side of the body, slurred speech), or renal problems (significantly decreased urine output, unusual swelling, unexplained weight gain).

Healthcare providers should report any suspected adverse reactions through their national pharmacovigilance reporting system. In the EU, this is done through the national competent authority; in the US, through the FDA MedWatch program. Post-marketing surveillance continues to play a crucial role in monitoring the safety profile of ketorolac and identifying rare adverse effects that may not have been detected during pre-approval clinical trials.

How Should You Store Ketorolac S.A.L.F.?

Proper storage of ketorolac injection is essential to maintain the stability, sterility, and efficacy of the medication. Ketorolac S.A.L.F. solution for injection should be stored at a temperature not exceeding 25°C (77°F). The ampoules should be kept in their original outer packaging to protect the solution from light, as ketorolac can undergo photodegradation when exposed to direct sunlight or strong artificial light for prolonged periods.

The solution must not be frozen. Freezing can alter the concentration and physical properties of the formulation, potentially affecting the sterility and efficacy of the product. If the solution has been inadvertently frozen, it should be discarded and not used, even if it appears to have returned to a normal liquid state after thawing.

Before administration, the solution should be visually inspected for clarity, color, and the absence of particulate matter. Ketorolac tromethamine solution for injection is normally a clear, slightly yellowish solution. If the solution appears cloudy, discolored, or contains visible particles, it should not be used. The ampoule is intended for single use only; any unused portion remaining after administration should be discarded immediately and not stored for later use.

As with all medications, ketorolac should be kept out of the sight and reach of children. Do not use Ketorolac S.A.L.F. after the expiration date printed on the ampoule and outer packaging. The expiration date refers to the last day of that month. Healthcare facilities should follow their institutional policies for medication storage, including temperature monitoring and stock rotation (first-in, first-out) to ensure that expired products are not administered to patients.

What Does Ketorolac S.A.L.F. Contain?

The active ingredient in Ketorolac S.A.L.F. is ketorolac tromethamine (also known as ketorolac trometamol in some markets), present at a concentration of 30 mg per milliliter. Ketorolac tromethamine is the tromethamine (tris) salt of ketorolac, a racemic mixture of the R-(+) and S-(-) enantiomers. The analgesic activity resides primarily in the S-(-) enantiomer, which is approximately 100 times more potent as a COX inhibitor than the R-(+) enantiomer. The molecular formula of ketorolac tromethamine is C₁₉H₂₄N₂O₆ with a molecular weight of 376.41 g/mol.

The excipients (inactive ingredients) in the formulation serve important pharmaceutical functions:

• Sodium chloride: Used to adjust the tonicity (osmolality) of the solution to make it isotonic with body fluids, minimizing pain and tissue irritation at the injection site.
• Ethanol: Present in a small quantity as a co-solvent to enhance the solubility and stability of ketorolac tromethamine in the aqueous formulation.
• Sodium hydroxide and/or hydrochloric acid: Used for pH adjustment. The solution is buffered to a pH range of approximately 6.9–7.9, which is close to physiological pH and minimizes irritation upon injection.
• Water for injections: The vehicle (solvent) for the formulation, prepared to meet strict pharmacopoeial standards for sterility and pyrogen-free requirements.

The formulation does not contain preservatives and is packaged in single-use glass ampoules. The absence of preservatives is important for minimizing the risk of hypersensitivity reactions and is consistent with the single-use nature of the product. Patients with known hypersensitivity to any of the excipients listed above should not receive this medication. Patients with a history of sensitivity to ethanol should inform their healthcare provider, although the quantity of ethanol in the injection is extremely small and clinically insignificant in terms of alcohol exposure.